SCHEMBL2107604

SCHEMBL2107604

COc1ccccc1-c1nc(COc2ccc3c(=O)c(-c4ccc(O)cc4)coc3c2)no1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.57
ALDH2 P05091 15/20 0.57
MAOA P21397 7/20 0.57
MAOB P27338 7/20 0.57
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 2/20 0.55
CYP3A4 P08684 2/20 0.55
HPGD P15428 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
HSD17B10 Q99714 2/20 0.55
USP2 O75604 1/20 0.55
GLA P06280 1/20 0.55
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPT P10636 2/20 0.52
TP53 P04637 1/20 0.52
BCL2 P10415 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3733212 0.95 TERT (0.55) XDHALDH2MAOAMAOBALDH1A1
SCHEMBL4090429 0.93 ALDH1A1 (0.50) XDHALDH2MAOAMAOBALDH1A1
SCHEMBL4090316 0.89 XDH (0.66) XDHALDH2MAOAMAOBALDH1A1
SCHEMBL2108020 0.88 ALDH2 (0.61) ALDH2MAOAMAOB
SCHEMBL3666659 0.87 ALDH2 (0.59) ALDH2MAOAMAOB
SCHEMBL2108760 0.86 XDH (0.63) XDHALDH2MAOAMAOBALDH1A1
SCHEMBL3663522 0.86 ALDH2 (0.55) XDHALDH2MAOAMAOB
SCHEMBL2108143 0.85 ALDH2 (0.60) XDHALDH2MAOAMAOBALDH1A1
SCHEMBL3670268 0.85 XDH (0.53) XDHALDH2MAOAMAOBALDH1A1
SCHEMBL2106733 0.84 ALDH2 (0.57) XDHALDH2MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158810-B2 ALDH-2 inhibitors in the treatment of addiction GILEAD SCIENCES, INC. (US) 2012-04-17 US disclosed
EP-2231149-A2 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS CV Therapeutics Inc. (US) 2010-09-29 EP disclosed
US-20090209533-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2009-08-20 US disclosed
US-20090124672-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS AMYGDALA NEUROSCIENCES, INC. 2009-05-14 US disclosed
WO-2009061924-A2 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS CV THERAPEUTICS, INC. (US) 2009-05-14 WO disclosed
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-08-28 US disclosed
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION ALDH1A1, ADH1A, ALDH3A1 XDH 78/4885ALDH2 5/4885MAOA 62/4885
US-20090209533-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION ALDH1A1, ADH1A, ALDH3A1 XDH 78/4885ALDH2 5/4885MAOA 62/4885
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION ALDH1A1, ADH1A, ALDH3A1 XDH 83/4885ALDH2 4/4885MAOA 62/4885
US-20090124672-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS ALDH2, ALDH1A2, ALDH1A1 XDH 117/4885ALDH2 1/4885MAOA 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.